Shopping Cart
- Remove All
- Your shopping cart is currently empty
FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM).
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,120 | 8-10 weeks | |
50 mg | $2,780 | 8-10 weeks | |
100 mg | $3,700 | 8-10 weeks |
Description | FT671 is a non-covalent and selective inhibitor of USP7 (IC50: 52 nM) It also binds to the USP7 catalytic domain (Kd: 65 nM). |
Targets&IC50 | USP7:52 nM |
In vitro | FT671 promotes the degradation of N-Myc and enhances p53 levels in the neuroblastoma cell line IMR-32, as well as in HCT116 and bone osteosarcoma (U2OS) cell lines. This results in the activation of p53 target genes, including BBC3 (which encodes PUMA), CDKN1A (p21), RPS27L (S27L), and MDM2. Additionally, in the MM.1S multiple myeloma cell line, FT671 stabilizes p53, associated with an upsurge in MDM2 ubiquitination. This stabilization of p53 triggers the expression of its target genes. |
In vivo | FT671 is well-to related even at high doses. FT671 (100 mg/kg and 200 mg/kg, oral gavage, daily) treatment in mice causes an obviously dose-dependent inhibition of tumor growth. |
Molecular Weight | 533.48 |
Formula | C24H23F4N7O3 |
Cas No. | 1959551-26-8 |
Relative Density. | 1.56 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 50 mg/mL (93.72 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.